Study design
For each participant we defined the date of cohort entry (baseline) as the date of first biopsy identified in the database. After exclusion of patients with a new (n=23 784) or previous (n=1399) diagnosis of gastric cancer at baseline, we kept in our database 412 290 patients who underwent biopsy for non-malignant indications. We further excluded those who had previously undergone gastric resection or gastrectomy (n=5203), had missing or invalid national registration numbers (n=429), or had conflicting information (died or emigrated before baseline biopsy, n=1447). Finally, 405 211 eligible patients remained in the cohort, of whom 21.1% had at least one repeat endoscopy with biopsy result documented. We continued follow-up until the occurrence of gastric cancer, date of gastric resection, migration out of Sweden, death, or the end of follow-up (31 December 2011), whichever occurred first.
Study designFor each participant we defined the date of cohort entry (baseline) as the date of first biopsy identified in the database. After exclusion of patients with a new (n=23 784) or previous (n=1399) diagnosis of gastric cancer at baseline, we kept in our database 412 290 patients who underwent biopsy for non-malignant indications. We further excluded those who had previously undergone gastric resection or gastrectomy (n=5203), had missing or invalid national registration numbers (n=429), or had conflicting information (died or emigrated before baseline biopsy, n=1447). Finally, 405 211 eligible patients remained in the cohort, of whom 21.1% had at least one repeat endoscopy with biopsy result documented. We continued follow-up until the occurrence of gastric cancer, date of gastric resection, migration out of Sweden, death, or the end of follow-up (31 December 2011), whichever occurred first.
การแปล กรุณารอสักครู่..
